Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4% and cutting sample processing time by up to 78%

- Beckman Coulter today announced the launch of its DxU Iris Workcell at the AACC Annual Scientific Meeting & Clinical Lab Expo. The DxU Iris Workcell is a fully automated system that streamlines urinalysis workflow and reduces manual reviews to 4%. The new workcell will be showcased in a live launch event held in the AACC Expo hall, booth 1523, and live streamed via LinkedIn on September 28, 2021 at 12 p.m. EDT 9 a.m. PDT .


A routine urinalysis is one the most frequently ordered tests, representing up to 30% of all samples received in the lab 3 . Many of these samples require a lab technician to perform a manual inspection, which causes workflow disruption and a substantial increase in workload. Whether it is confirming the analyzer's findings or identifying unique particle types, manual microscopic reviews are time-consuming and can take up to six times longer per sample than with an automated system 4 .

Automating the routine urinalysis workflow with the DxU Iris Workcell reduces sample subjectivity and variability, helping laboratories of all sizes standardize processes, drive faster turnaround time and deliver quality results.

"There is no doubt that the pandemic has intensified pressure on the clinical laboratory," said Dr. Peter Soltani , senior vice president & general manager, hematology, urinalysis & workflow information technology solutions at Beckman Coulter. "In this pressurized environment, manual reviews are particularly onerous because they are labor-intensive, taking time and focus away from scientific work. We designed the DxU Iris Workcell to allow urinalysis operators to automatically classify sediment particles, minimizing the need for human intervention."

The DxU Iris Workcell pairs the DxU 850m Iris or DxU 840m Iris urine microscopy analyzer with the Arkray AUTION MAX™ 4030 urine chemistry analyzer to create a scalable, fully automated urinalysis solution. The workcell was developed with proprietary Digital Flow Morphology technology with Auto-Particle Recognition (APR) Software to enable laboratories to deliver standardized results using artificial intelligence (AI). This industry-leading technology isolates, identifies and characterizes urine particles to provide immediate, accurate and reproducible results verified directly on the screen.

"As a Med Tech, it's important for me that any new analyzer we bring into the lab makes the workflow better and is easy to use with minimal maintenance. The DxU Iris has several features that can help med techs work more efficiently. One such feature is that the user guide with the key reference information is on the main screen," said Jennifer Soria , a hematology section coordinator for a medical group in Florida . "I love the new Load and Unload station as it can hold multiples racks, allowing users to work in other areas of the lab while processing urine samples."

The DxU Iris Workcell is designed for high-volume laboratories and features:

  • An optional Load and Unload station that increases the capacity of racks for a total of 190 onboard samples
  • Intuitive software user interface to comfortably navigate the analyzer menu, access key reference information and simplify user training in a format aligned across multiple Beckman Coulter instruments including hematology, chemistry and immunoassay
  • Connectivity with Beckman Coulter's advanced informatics software solutions: PRO Service remote service tool, DxONE Command Central remote monitoring, and REMISOL Advance middleware

To learn more about Beckman Coulter's DxU Iris Workcell and other urinalysis solutions, visit the website at www.beckmancoulter.com/DxUIris .

Members of the media can access the online press kit for the DxU Iris Workcell, including videos, images, and other assets at www.beckmancoulter.com/DxUIris-Media .

About Beckman Coulter
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory's role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing and found in hospitals, reference laboratories, and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes, and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics, and unlocking hidden value through performance partnership. A subsidiary of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter, Inc. is headquartered in Brea, Calif. , and has more than 11,000 global associates working diligently to make the world a healthier place.

© 2021 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 2021-9662

ARKRAY, the stylized logo, and the ARKRAY products mentioned herein are trademarks or registered trademarks of ARKRAY in the United States .

REMISOL Advance is a trademark or registered trademark of Normand-Info SAS in the United States and other countries. Used under license.

References:
1 Broadlawns Medical Center. (2019). Manual microscopy divided by on-screen microscopic verification report generated December 20, 2019 . A case study published by Beckman Coulter. https://media.beckmancoulter.com/-/media/diagnostics/products/urinalysis/docs/ua-broadlawns-case-study.pdf .
2 Beaufort Memorial Urinalysis Workflow Case Study, CS-52048.
3 Delanghe, J., & Speeckaert, M. (2014). Preanalytical requirements of urinalysis. Biochemia Medica, 24(1), 89–104. https://doi.org/10.11613/BM.2014.011
4 https://www.mlo-online.com/home/article/13004799/automated-urinalysis-in-the-clinical-lab [Accessed: August 2, 2021 ]

DxU Iris Workcell

DxU Iris Workcell

DxU Iris Workcell

Beckman Coulter logo. (PRNewsfoto/Beckman Coulter)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/beckman-coulters-new-urinalysis-solution-improves-laboratory-workflow-by-significantly-reducing-manual-reviews-to-41-and-cutting-sample-processing-time-by-up-to-782-301386105.html

SOURCE Beckman Coulter Diagnostics

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

Star Jones , award winning television personality & women's heart health advocate,   helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S. many women are still unaware of the risk and the importance of heart health.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×